Synthesis, antiplasmodial activity and in silico molecular docking study of pinocembrin and its analogs

BMC Chemistry

Table 1 In vivo suppressive effect of pinocembrin and its analogs against P. berghei in Swiss albino mice

No.	Doses (mg/kg)	Parasitological effect		MST ± SEM	Body Weight ± SEM
No.	Doses (mg/kg)	%Parasitaemia ± SEM	%Suppression	MST ± SEM	D0	D4
6a	NC	59.00 ± 0.78^a	0.00	7.00 ± 0.32	24.00 ± 0.63	22.92 ± 0.84
	15	57.00 ± 1.28^b	21.69 ^b	9.60 ± 0.40	24.38 ± 0.91	23.38 ± 0.93
	20	40.00 ± 0.79 ^bc	32.20 ^bc	10.40 ± 0.87	22.98 ± 0.80	22.38 ± 0.57
	25	46.92 ± 1.17^c	35.92^c	12.00 ± 0.55	23.90 ± 0.78	23.36 ± 0.54
	30	38.08 ± 0.56^c	38.04^c	13.60 ± 0.87	23.44 ± 0.63	22.72 ± 0.53
	35	34.80 ± 0.86^d	49.09^d	11.60 ± 0.40	23.70 ± 0.56	22.87 ± 0.69
6b	NC	39.85 ± 0.80^a	0.00	7.60 ± 0.25	24.38 ± 0.56	23.60 ± 0.58
6b	20	29.62 ± 1.21^b	25.52^b	7.60 ± 0.68	23.92 ± 0.74	22.74 ± 0.64
6c	NC	77.40 ± 1.60^a	0.00	6.80 ± 0.66	23.68 ± 0.98	22.26 ± 0.93
6c	20	51.50 ± 1.14^b	33.46^b	11.80 ± 0.37	23.44 ± 0.78	22.74 ± 0.87
6d	NC	39.85 ± 0.80a	0.00	7.60 ± 0.25	24.38 ± 0.56	23.60 ± 0.58
6d	30	36.23 ± 2.20a	8.90 a	6.60 ± 0.30	24.32 ± 0.45	22.60 ± 0.65
6e	NC	59.00 ± 0.78^a	0.00	7.00 ± 1.28	24.00 ± 0.63	22.92 ± 0.84
6e	20	26.14 ± 0.93^b	55.57^b	14.60 ± 0.51	24.52 ± 0.58	24.52 ± 0.56
6i	NC	73.22 ± 1.25^a	0.00	7.80 ± 0.37	23.66 ± 0.57	22.04 ± 0.46
	15	60.46 ± 0.78^b	17.42^b	8.80 ± 0.49	23.06 ± 0.60	22.06 ± 0.59
	25	51.30 ± 0.44^c	29.05^c	8.00 ± 0.45	23.12 ± 0.47	22.90 ± 1.02
	30	43.58 ± 0.62^d	40.45^d	13.6 ± 1.03	23.70 ± 0.68	23.50 ± 0.65
7a	NC	33.25 ± 1.16^a	0.00	7.40 ± 0.51	24.24 ± 0.64	23.50 ± 0.65
	20	8.5 0 ± 0.41^b	74.41^b	13.60 ± 1.25	23.70 ± 0.47	23.30 ± 0.49
	30	4.26 ± 0.13^c	87.19^c	14.40 ± 0.87	24.54 ± 0.58	24.06 ± 0.63
CQ¹	30	0.00	100.00	21 <

NC Negative control; Means with different letters are significantly different (P < 0.05); P-value is set for the comparison between treated and NC groups; CQ: Chloroquine; ¹has been used as positive control for the test of all compounds

ISSN: 2661-801X